N-(2,2-Dimethyl-4-oxochroman-6-yl)acetamide
|
- $70.69 - $732
- Product name: N-(2,2-Dimethyl-4-oxochroman-6-yl)acetamide
- CAS: 186774-61-8
- MF: C13H15NO3
- MW: 233.26
- EINECS:
- MDL Number:MFCD19380257
- Synonyms:N-(2,2-Dimethyl-4-oxochroman-6-yl)acetamide;Acetamide, N-(3,4-dihydro-2,2-dimethyl-4-oxo-2H-1-benzopyran-6-yl)-
4 prices
Selected condition：
Brand
- Alichem
- Atlantic Research Chemicals
- Crysdot
- Matrix Scientific
Package
- 250mg
- 1g
- 50mgs:
- ManufacturerAlichem
- Product number186774618
- Product descriptionN-(2,2-dimethyl-4-oxochroman-6-yl)acetamide
- Packaging250mg
- Price$252.72
- Updated2021-12-16
- Buy
- ManufacturerAtlantic Research Chemicals
- Product numberXS100271
- Product descriptionN-(2,2-Dimethyl-4-oxochroman-6-yl)acetamide 95%
- Packaging50mgs:
- Price$70.69
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11177807
- Product descriptionN-(2,2-Dimethyl-4-oxochroman-6-yl)acetamide 95+%
- Packaging1g
- Price$579
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number115006
- Product descriptionN-(2,2-Dimethyl-4-oxochroman-6-yl)acetamide 97%
- Packaging1g
- Price$732
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Alichem | 186774618 | N-(2,2-dimethyl-4-oxochroman-6-yl)acetamide | 250mg | $252.72 | 2021-12-16 | Buy |
| Atlantic Research Chemicals | XS100271 | N-(2,2-Dimethyl-4-oxochroman-6-yl)acetamide 95% | 50mgs: | $70.69 | 2021-12-16 | Buy |
| Crysdot | CD11177807 | N-(2,2-Dimethyl-4-oxochroman-6-yl)acetamide 95+% | 1g | $579 | 2021-12-16 | Buy |
| Matrix Scientific | 115006 | N-(2,2-Dimethyl-4-oxochroman-6-yl)acetamide 97% | 1g | $732 | 2021-12-16 | Buy |
Properties
Boiling point :440.0±45.0 °C(Predicted)
Density :1.194±0.06 g/cm3(Predicted)
pka :14.10±0.40(Predicted)
Density :1.194±0.06 g/cm3(Predicted)
pka :14.10±0.40(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|